A pilot study of the impact of high-frequency chest wall oscillation in chronic obstructive pulmonary disease patients with mucus hypersecretion

International Journal of COPD

Volumn 6, Issue 1, 2011, Pages 693-699

  Chakravorty, Indranil ^a   Chahal, Kamaljit ^b   Austin, Gillian ^b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b LISTER HOSPITAL   (United Kingdom)

Author keywords

Bronchiectasis; Sputum volume; Symptom scopes

Indexed keywords

AGED; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FORCED VITAL CAPACITY; HIGH FREQUENCY VENTILATION; HUMAN; LUNG FUNCTION TEST; MALE; MUCUS HYPERSECRETION; OUTCOME ASSESSMENT; PILOT STUDY; PREDICTION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SPUTUM ANALYSIS; SYNDROME DELINEATION; TREND STUDY; CHEST WALL OSCILLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEASIBILITY STUDY; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; LUNG; MIDDLE AGED; MUCOCILIARY CLEARANCE; MUCUS; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; SECRETION; SPUTUM; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; UNITED KINGDOM; VITAL CAPACITY;

AGED; AGED, 80 AND OVER; CHEST WALL OSCILLATION; CROSS-OVER STUDIES; ENGLAND; FEASIBILITY STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LINEAR MODELS; LUNG; MALE; MIDDLE AGED; MUCOCILIARY CLEARANCE; MUCUS; PILOT PROJECTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SPUTUM; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84863798119     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S22896     Document Type: Article

References (31)

1. Mapel D, Chen JC, George D, Halbert RJ. The cost of chronic obstructive pulmonary disease and its effects on managed care. Manag Care Interface. 2004;17:61-66.
2. Miller RM, George D, Halbert RJ. Improving the management of chronic obstructive pulmonary disease. J Healthc Qual. 2005;27:42-47.
3. Sin DD, Man SFP. Pharmacotherapy for mortality reduction in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3:624-629.
4. Niewoehner DE. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. Am J Med. 2006;119(10 suppl 1):38-45.
5. Silverman EK. Exacerbations in chronic obstructive pulmonary disease: do they contribute to disease progression? Proc Am Thorac Soc. 2007;4:586-590.
6. Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med. 2008;177:396-401.
7. Makris D, Moschandreas J, Damianaki A, et al. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med. 2007;101:1305-1312.
8. Pryor JA. Physiotherapy for airway clearance in adults. Eur Respir J. 1999;14:1418-1424.
9. Wolkove N, Baltzan MA Jr, Kamel H, Rotaple M. A randomized trial to evaluate the sustained efficacy of a mucus clearance device in ambulatory patients with chronic obstructive pulmonary disease. Can Respir J. 2004;11:567-572.
10. Livraghi A, Randell SH. Cystic fibrosis and other respiratory diseases of impaired mucus clearance. Toxicol Pathol. 2007;35:116-129.
11. Kendrick AH. Airway clearance techniques in cystic fibrosis. Eur Respir J. 2006;27:1082-1083.
12. Tarran R. Regulation of airway surface liquid volume and mucus transport by active ion transport. Proc Am Thorac Soc. 2004;1:42-46.
13. King M, Phillips DM, Zidulka A, Chang HK. Tracheal mucus clearance in high-frequency oscillation. II: chest wall versus mouth oscillation. Am Rev Respir Dis. 1984;130:703-706.
14. van der Schanns C P. Conventional chest physical therapy for obstructive lung disease. Respir Care. 2007;52:1198-1206.
15. Button B, Boucher RC. Role of mechanical stress in regulating airway surface hydration and mucus clearance rates. Respir Physiol Neurobiol. 2008;163:189-201.
16. Vestbo J, Prescott E, Lange P. Association of chronic mucus hyperse-cretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med. 1996;153:1530-1535.
17. Hogg JC. Pathophysiology of airfow limitation in chronic obstructive pulmonary disease. Lancet. 2004;364:709-721.
18. Rodriguez-Roisin R. The airway pathophysiology of COPD: implications for treatment. COPD. 2005;2:253-262.
19. Kobylianskii VI, Gamal EA. Mucoactive therapy and new aspects of the pathogenesis of chronic obstructive pulmonary disease. Klin Med (Mosk). 2006;84:15-24.
20. Bhowmik A, Chahal K, Austin G, Chakravorty I. Improving mucociliary clearance in chronic obstructive pulmonary disease. Respir Med. 2009;103:496-502.
21. Jones P W, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med. 1991;85 Suppl B:25-31; discussion 33-37.
22. Kempainen RR, Williams CB, Hazelwood AR, et al. Comparison of high-frequency chest wall oscillation with differing waveforms for airway clearance in cystic fibrosis. Chest. 2007;132:1227-1232.
23. Lange DJ, Lechtzin N, Davey C, et al, High-frequency chest wall oscillation in ALS: an exploratory randomized, controlled trial. Neurology. 2006;67:991-997.
24. Piquet J, Brochard L, Isabey D, et al. High frequency chest wall oscillation in patients with chronic air-flow obstruction. Am Rev Respir Dis. 1987;136:1355-1359.
25. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care. 2003;48:1204-1213.
26. Their SL, Yu-Isenberg KS, Leas B F, et al. In chronic disease, nationwide data show poor adherence by patients to medication and by physicians to guidelines. Manag Care. 2008;17:48-52.
27. Gillisen A. Patients' adherence in asthma. J Physiol Pharmacol. 2007; 58(Suppl 5):205-222.
28. Jones P W. St George's Respiratory Questionnaire: MCID. COPD. 2005; 2:75-79.
29. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132:1565-1572.
30. Pistolesi M, Camiciottoli G, Paoletti M, et al. Identification of a predominant COPD phenotype in clinical practice. Respir Med. 2008;102:367-376.
31. Patterson JE, Hewitt O, Kent L, et al. Acapella versus 'usual airway clearance' during acute exacerbation in bronchiectasis: a randomized crossover trial. Chron Respir Dis. 2007;4:67-74.